CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 18 enrolled
Drug / intervention
folinic aciddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03771560
NCT03771560Phase 3Completed
CompareCT.gov

An Examination of Changes in Urinary Metabolites With Use of Folinic Acid in Children With Autism Spectrum Disorder (ASD)

University of California, San Francisco·interventional·Posted Dec 11, 2018·Updated Dec 3, 2019

In Brief

A Phase 3 clinical trial evaluating folinic acid for Autism Spectrum Disorder. Completed, enrolled 18 participants across 1 site.

Detailed Summary

An examination of changes in urinary metabolites with use of folinic acid in children with autism spectrum disorder (ASD). Investigators will also measure behavioral measures and academic measures monthly at school with teachers and parents report.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutism Spectrum Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedDec 11, 2018
Enrollment StartFeb 15, 2018
Primary CompletionJun 30, 2018
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7.6 years ago

Interventions

folinic aciddrug

subject will take folinic acid daily for 12 weeks